glp 1 heart disease Frontiers JCI - Cardioprotective GLP-1 metabolite

These are different trials, not head-to-head data, but many providers consider tirzepatide stronger

The complex pathophysiology and the metabolic risk factors shared between type 2 diabetes, obesity, CKD and cardiovascular disease have led to the concept of a cardiovascularkidneymetabolic (CKM) syndrome

Studies in humans should be done (42, 43) ( Table 1 )

It's one of the only venomous lizards in North America, and its bite while rarely fatal to us is pretty unpleasant

In fact, the opposite may be true

Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice